PEGVISOMANT

Other

Brand names: SOMAVERT

Oral

Mechanism of Action

12.1 Mechanism of Action Pegvisomant selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of IGF-1, as well as other GH-responsive serum proteins such as free IGF-1, the acid-labile subunit of IGF-1 (ALS), and insulin-like growth factor binding protein-3 (IGFBP-3).

Indications

1 INDICATIONS AND USAGE SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy

or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels. ( 1 )

Contraindications

• 4 CONTRAINDICATIONS None. None. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Hypoglycemia : Monitor blood glucose in patients with diabetes mellitus and reduce anti-diabetic drug therapy as necessary

Known Side Effects

9 documented side effects by frequency

Drug Not Working

1-10%

Headache

1-10%

Fatigue

1-10%

Joint Pain

1-10%

Injection Site Pain

1-10%

Diarrhea

1-10%

Nausea

1-10%

High Blood Pressure

0.1-1%

General Unwellness

0.1-1%

Community Discussions

No community discussions found for PEGVISOMANT yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral